Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Milestone Pharmaceuticals Inc. - Common Shares (NQ:MIST)

1.300 -0.060 (-4.41%)
Streaming Delayed Price Updated: 2:45 PM EDT, Mar 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Milestone Pharmaceuticals Inc. - Common Shares

< Previous 1 2 3 Next >
What's going on in today's session ↗
Via Chartmill
Milestone Pharmaceuticals (NASDAQ:MIST) Reports First Revenue with Q4 2025 Earnings, Beats Estimates ↗
Via Chartmill
Topics Earnings
News headline image
Synergy CHC Corp. (NASDAQ: SNYR) Expands FOCUSfactor® Beverage Platform Further Building Shareholder Value – IMG, YCBD, SURG, URG Inside
Via AB Newswire
News headline image
MIST Stock Soars Pre-Market After FDA Approves First Commercial Product – Retail Remains Bullish, Dismisses ‘Sell The News’ Concerns ↗
Milestone stated in its announcement that the approval of Cardamyst opens up an addressable market of more than two million Americans who suffer from PSVT. 
Via Stocktwits
News headline image
Milestone Pharmaceuticals: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
Monday's pre-market session: top gainers and losers ↗
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Milestone Pharmaceuticals (NASDAQ:MIST) Posts Narrower-Than-Expected Q3 Loss as Key FDA Decision Looms ↗
Milestone Pharmaceuticals beat Q3 earnings estimates, with a narrower loss. The stock rose as investors await the December 2025 FDA decision for its lead drug, CARDAMYST™. 
Via Chartmill
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Which stocks are moving on Friday? ↗
Stay up-to-date with the latest market trends in the middle of the day on Friday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
Why Is Milestone Pharmaceuticals Stock Plunging On Friday? ↗
FDA accepts Milestone's response on Cardamyst nasal spray, sets new PDUFA date; company raises $52.5 million to support potential PSVT treatment launch. 
Via Benzinga
News headline image
Dow Dips Over 200 Points; Levi Strauss Posts Upbeat Earnings ↗
 
Via Benzinga
Topics Stocks
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Wondering what's happening in today's pre-market session? ↗
The US market session of Friday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Top movers analysis one hour before the close of the markets on 2025-03-28: top gainers and losers in today's session. ↗
Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Top movers in Friday's session ↗
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s Positive ↗
The FDA said an inspection is required at a facility where the company performed release testing for the product to ensure it complies with Current Good Manufacturing Practices. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Traders are paying attention to the gapping stocks in Friday's session. ↗
Let's have a look at what is happening on the US markets on Friday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Dow Tumbles Over 500 Points; Abacus Global Management Shares Spike Higher ↗
 
Via Benzinga
Topics Stocks
News headline image
Top movers in Friday's pre-market session ↗
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
News headline image
Why Is Milestone Pharmaceuticals Stock Plunging Today? ↗
Milestone Pharmaceuticals' stock drops over 61% after receiving a Complete Response Letter from the FDA for its CARDAMYST NDA. 
Via Benzinga
News headline image
Nasdaq Down 100 Points; Federal Reserve's Favorite Inflation Gauge Increases More Than Expected ↗
 
Via Benzinga
Topics Economy
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
MIST Stock Earnings: Milestone Pharmaceuticals Beats EPS for Q2 2024 ↗
MIST stock results show that Milestone Pharmaceuticals beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
MIST Stock Earnings: Milestone Pharmaceuticals Beats EPS for Q1 2024 ↗
MIST stock results show that Milestone Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
MIST Stock Earnings: Milestone Pharmaceuticals Misses EPS for Q4 2023 ↗
MIST stock results show that Milestone Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.